Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis
Bazedoxifene versus Oral Bisphosphonates for the Prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture a network meta-analysis.pdf
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Luo, X
Cappelleri, JC
Chines, A
Sutradhar, S
Jansen, JP
Language :
English
Title :
Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis
C.L. Deal Osteoporosis: prevention, diagnosis, and management Am J Med 102 Suppl. 1997 35S 39S
R. Burge, B. Dawson-Hughes, and D.H. Solomon et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 2007 465 475
O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 2006 1726 1733
J.A. Kanis, and O. Johnell Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 2005 229 238
M. Stevenson, M.L. Jones, and E. De Nigris et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis Health Technol Assess 9 2005 100 160
M. Stevenson, S. Davis, and M. Lloyd-Jones et al. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women Health Technol Assess 11 2007 100 134
European Medicines Agency. Assessment report for Conbriza. Procedure No. EMEA/H/C/913. 2009. Available from: http://www.emea.europa.eu/ema/index.jsp? curl=pages/medicines/human /medicines/000913/human-med-000723.jsp. [Accessed October 19, 2011].
H. Kawate, and R. Takayanagi Efficacy and safety of bazedoxifene for postmenopausal osteoporosis Clin Interv Aging 6 2011 151 156
FRAX. WHO Fracture Assessment Tool. Available from: http://www.shef.ac. uk/FRAX/. [Accessed October 19, 2011].
National Institute for Health and Care Excellence. The guidelines manual 2009. Available from: http://www.nice.org.uk/aboutnice/howwework/ developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/ GuidelinesManual2009.jsp?domedia=1&mid=60B7B3CD-BBC2-E1BE-A6D53FD68D8845AD. [Accessed October 19, 2011].
D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 897 900
D.C. Hoaglin, N. Hawkins, and J.P. Jansen et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2 Value Health 14 2011 429 437
J.P. Jansen, R. Fleurence, and B. Devine et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 Value Health 14 2011 417 428
G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
A.J. Sutton, and K.R. Abrams Bayesian methods in meta-analysis and evidence synthesis Stat Methods Med Res 10 2001 277 303
D. Spiegelhalter, A. Thomas, and N. Best et al. WinBUGS User Manual: Version 1.4 2003 MRC Biostatistics Unit Cambridge
S.L. Silverman, C. Christiansen, and H.K. Genant et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 2008 1923 1934
S. Boonen, R.F. Laan, and I.P. Barton et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies Osteoporos Int 16 2005 1291 1298
H.G. Bone, R.W. Downs Jr, and J.R. Tucci et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers J Clin Endocrinol Metab 82 1997 265 274
U.A. Liberman, S.R. Weiss, and J. Bröll et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1995 1437 1443
C.H. Chesnut III, A. Skag, and C. Christiansen et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 2004 1241 1249
C.H. Chesnut, M.P. Ettinger, and P.D. Miller et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE Curr Med Res Opin 21 2005 391 401
D.M. Black, S.R. Cummings, and D.B. Karpf et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348 1996 1535 1541
S.R. Cummings, D.M. Black, and D.E. Thompson et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
H.A. Pols, D. Felsenberg, and D.A. Hanley et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporos Int 9 1999 461 468
M.R. McClung, P. Geusens, and P.D. Miller et al. Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 2001 333 340
J. Reginster, H.W. Minne, and O.H. Sorensen et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 2000 83 91
S.T. Harris, N.B. Watts, and H.K. Genant et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
I. Fogelman, C. Ribot, and R. Smith et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group J Clin Endocrinol Metab 85 2000 1895 1900
